Novo Nordisk A/S
NOV.DE
Deutsche Börse43.07
EUR
-0.57
- -
Novo Nordisk A/S
NOV.DE
(Deutsche Börse)
Recent
price
43.07
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Novo Nordisk A/S is a global pharmaceutical company specializing in the development, manufacturing, and marketing of healthcare products primarily for diabetes care, obesity, rare bleeding disorders, growth hormone therapy, and hormone replacement therapy. The company’s core products include diabetes medications such as semaglutide marketed under brand names Ozempic and Rybelsus, obesity treatment Wegovy, insulin products including Levemir, Tresiba, NovoLog, and NovoRapid, as well as rare disease therapies like NovoSeven and NovoEight for hemophilia. Additional offerings includeGlucaGen and Zegalogue for hypoglycemia, Sogroya for growth hormone deficiency, and Rivfloza for rare kidney disorders. Novo Nordisk operates across multiple regions worldwide with a strong presence in North America, Europe, and emerging markets, serving a broad base of healthcare providers, hospitals, and governments, with headquarters in Denmark and founding year 1923. In recent years, Novo Nordisk has made several strategic expansions and operational changes. It has reported robust sales growth driven by its obesity care segment, with sales increasing by over 37% in 2025, and ongoing growth in diabetes and rare disease treatments. The company has successfully filed for FDA approval for a higher dose of Wegovy injection (7.2 mg) and advanced its pipeline with the phase 3 development of a first-in-class amylin monotherapy, cagrilintide, for weight management. Novo Nordisk acquired Akero Therapeutics, enhancing its portfolio with a Phase 3 FGF21 analogue for metabolic dysfunction-associated steatohepatitis (MASH), and also acquired Omeros’ MASP-3 inhibitor zaltenibart for rare blood disorders. Partnerships include an expanded R&D collaboration with Ginkgo Bioworks focusing on synthetic biology technologies to improve manufacturing processes and pipeline discovery. Additionally, Novo Nordisk launched its blockbuster diabetes drug Ozempic in India in late 2025 to expand its geographic footprint. The company also entered a technology development partnership with Evotec SE to support stem cell-based therapies development and manufacturing capabilities. Operationally, the company has undergone restructuring initiatives to streamline operations and reinvest in future growth areas, including digital innovation in drug discovery and clinical trial optimization. Novo Nordisk operates primarily in the pharmaceutical industry focusing on therapeutic segments of diabetes care, obesity, rare diseases, and hormone-related treatments. Its customer base includes healthcare professionals, hospitals, national health services, and pharmaceutical distributors across the Americas, Europe, Asia Pacific, and other markets. The company maintains a robust global supply chain and a strategic emphasis on innovation driven by external partnerships and acquisitions to diversify its modality portfolio beyond injectable GLP-1 therapies. Founded in 1923 and headquartered in Bagsværd, Denmark, Novo Nordisk continues to lead in diabetes and obesity therapies while expanding into next generation treatments for rare diseases and metabolic conditions through robust R&D and strategic acquisitions, reinforcing its position as a leading global biopharmaceutical company. This description reflects information up to December 2025 including the latest product approvals, acquisitions, partnerships, and market launches.